biomedicines

IMPACT FACTOR 3.9

Indexed in: PubMed

CITESCORE 6.8

an Open Access Journal by MDPI

Application of Liposomes in Cancer

Guest Editor:

Dr. Shiyan Dong
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Deadline for manuscript submissions:
closed (31 May 2024)

Message from the Guest Editor

Chemotherapy has a crucial role in cancer treatment; however, conventional cytotoxic drugs often lack specificity for targeting cancer cells. Additionally, many anticancer agents possess high toxicity, hydrophobic properties, and short half-lives, which limit their effectiveness in cancer therapy. The emergence of nanotechnology has paved the way for the development of efficient nanoscale drug delivery systems, known as nanoparticles, for various diseases. Among these delivery systems, lipid-based nanoparticles, including natural lipid nanoparticles (exosomes) as well as synthetic nanoparticles (liposomes), have been shown to be very effective in demonstrating the ability to: (1) enhance cancer chemotherapy; (2) reduce the cytotoxicity of anticancer drugs to normal tissues, thereby reducing their toxic side effects; (3) increase the solubility of hydrophobic drugs; and (4) provide prolonged and controlled release of drugs.

biomedicines

IMPACT FACTOR 3.9 | Indexed in: PubMed | CITESCORE 6.8

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI